Two Columbus Zoo elephants are expecting in the coming months
Experienced mama Phoebe and first-time mom Sunny are due in the coming months, which has the animal care team on baby watch.
'We've never had this opportunity to even have the ability to have two baby elephants at the same time. We are all-in with sustainability and conservation of Asian elephants and I cannot wait,' said Adam Felts, Senior Curator for the Columbus Zoo and Aquarium.
With any pregnancy, it's a delicate balance of excitement, anticipation and specialized care, which these elephants are receiving around the clock.
'Fortunately, they are months apart, or at least four months apart,' said Dr. Randy Junge, Columbus Zoo's Vice President of Animal Health. 'If the babies have complications or the moms have complications, they can be really intensive cases. If you had two at the same time with complications, it could be really very difficult, but we're not anticipating any problems again both females are healthy.'
Nationwide Arena announces $400 million renovation project
Keeping them healthy and limber is a top priority for the elephant care team members like Laura Garcia, who, on this day, was leading Pheobe in her morning stretches. 'We do call it elephant yoga, and we want to keep our elephants in shape, especially our pregnant and elephants,' said Garcia.
The team also does regular blood draws and ultrasounds to monitor mom and baby's health.
'At this stage, the baby isn't changing much, we just want to monitor and make sure there aren't any changes,' said Dr. Junge.
As the moms-to-be enter their birth windows this summer, the excitement is mounting for everyone.
'It's very exciting that people get excited about this with us because it is such a special experience,' said Garcia.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the Company's novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight—representing a 30-fold increase over the initial dose level. To date, no dose-limiting toxicities (DLTs) have been observed in the fourth cohort. Anixa's proprietary CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which preclinical research indicates is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells—but not in healthy tissue. The ongoing first-in-human clinical trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy. The Phase 1 study is designed to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity. "Our therapy continues to demonstrate a favorable safety profile, even at significantly higher cell doses," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "While this study is primarily designed to assess safety, we remain encouraged by early indications of potential efficacy as the trial progresses." Anixa's CAR-T technology was invented by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. The ongoing clinical trial is being conducted at Moffitt under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program. Anixa holds an exclusive worldwide license to the FSHR-targeting CAR-T technology from The Wistar Institute. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on LinkedIn, X, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
High Growth Tech Stocks in Asia Featuring Takara Bio and Two Others
As Asian markets continue to navigate a complex landscape of economic indicators and trade negotiations, the tech sector stands out with its potential for high growth, driven by innovation and evolving consumer demands. In this environment, identifying promising stocks involves looking for companies that demonstrate resilience and adaptability in the face of changing market conditions, such as those featured in our discussion on Takara Bio and two other noteworthy tech firms. Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Accton Technology 22.79% 22.79% ★★★★★★ Ugreen Group 20.48% 26.05% ★★★★★★ Shanghai Huace Navigation Technology 25.38% 24.34% ★★★★★★ PharmaEssentia 31.53% 65.34% ★★★★★★ Fositek 31.22% 40.16% ★★★★★★ Eoptolink Technology 33.64% 33.77% ★★★★★★ Shengyi Electronics 26.23% 37.08% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ eWeLLLtd 24.93% 24.09% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★ Click here to see the full list of 180 stocks from our Asian High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Takara Bio Simply Wall St Growth Rating: ★★★★☆☆ Overview: Takara Bio Inc. operates in the fields of reagents, equipment, contract services, and genetic medicine across various regions including Japan, China, Asia, the United States, and Europe with a market capitalization of ¥107.53 billion. Operations: Takara Bio generates revenue through its diverse operations in reagents, equipment, contract services, and genetic medicine across multiple regions. The company focuses on leveraging its expertise in biotechnology to provide innovative solutions for research and healthcare applications. Takara Bio, a contender in Asia's high-growth tech sector, showcases a robust earnings trajectory with an annual growth rate of 29.66%, significantly outpacing the broader Japanese market's 8%. Despite a substantial one-off loss of ¥531M impacting its recent financials, the company has demonstrated exceptional profit growth over the past year at 406.1%, dwarfing the biotech industry's average of 11.6%. However, challenges persist as its revenue growth projection stands at just 4.9% per year, slightly above Japan's market average but below high-growth benchmarks. The firm's R&D commitment is crucial for sustaining innovation and competitiveness in this rapidly evolving sector. Dive into the specifics of Takara Bio here with our thorough health report. Learn about Takara Bio's historical performance. Good Will Instrument Simply Wall St Growth Rating: ★★★★★☆ Overview: Good Will Instrument Co., Ltd. specializes in the production and distribution of electrical test and measurement instruments for educational and industrial manufacturing sectors, with a market cap of NT$7.57 billion. Operations: Good Will Instrument generates revenue primarily from the sale of electronic test and measurement instruments, totaling NT$2.85 billion. The company serves both educational and industrial manufacturing markets. Good Will Instrument, amid Asia's competitive tech landscape, is demonstrating robust growth with reported annual revenue and earnings increases of 50.8% and 49.5%, respectively. This performance significantly surpasses the TW market averages of 10.1% for revenue and 15.3% for earnings growth, highlighting its potential in a rapidly evolving sector. The company's commitment to innovation is evident from its R&D investments, crucial for maintaining its competitive edge in technology development. Recent financials reveal a strong upward trajectory with first-half sales reaching TWD 1.37 billion, up from TWD 1.32 billion year-over-year, complemented by a net income rise to TWD 174.4 million from TWD 146.28 million in the previous period. Click here to discover the nuances of Good Will Instrument with our detailed analytical health report. Review our historical performance report to gain insights into Good Will Instrument's's past performance. Sercomm Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sercomm Corporation is engaged in the research, development, manufacturing, and sale of networking communication software and equipment across North America, Europe, and the Asia Pacific with a market capitalization of NT$31.02 billion. Operations: The company's primary revenue stream comes from its computer networks segment, generating NT$50.45 billion. Sercomm's recent financial performance indicates a challenging phase, with second-quarter sales dropping to TWD 12.2 billion from TWD 13.7 billion year-over-year and net income falling significantly to TWD 334.32 million from TWD 545.21 million. Despite these setbacks, the company is actively enhancing its strategic partnerships, notably with Vecima Networks, to strengthen its position in the PON technology sector for broadband services—a move that could stabilize and potentially increase future revenue streams. Additionally, Sercomm has demonstrated a commitment to shareholder returns by repurchasing over 3 million shares for TWD 302.29 million earlier this year, reflecting confidence in its operational adjustments and market strategy moving forward. Get an in-depth perspective on Sercomm's performance by reading our health report here. Assess Sercomm's past performance with our detailed historical performance reports. Key Takeaways Click here to access our complete index of 180 Asian High Growth Tech and AI Stocks. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Want To Explore Some Alternatives? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TSE:4974 TWSE:2423 and TWSE:5388. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Exploring High Growth Tech Stocks In Asia
As global markets react to economic data and rate cut speculations, the Asian tech sector is drawing attention with its potential for high growth amidst easing U.S.-China trade tensions. In this dynamic environment, identifying stocks with strong innovation capabilities and resilience to market fluctuations can be key for investors looking to capitalize on the region's technological advancements. Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Accton Technology 22.79% 22.79% ★★★★★★ Shanghai Huace Navigation Technology 25.38% 24.34% ★★★★★★ PharmaEssentia 31.53% 65.34% ★★★★★★ Fositek 31.22% 40.16% ★★★★★★ Eoptolink Technology 33.64% 33.77% ★★★★★★ Shengyi Electronics 26.23% 37.08% ★★★★★★ Zhejiang Meorient Commerce Exhibition 26.71% 35.89% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ eWeLLLtd 24.93% 24.09% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★ Click here to see the full list of 180 stocks from our Asian High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Shanghai OPM Biosciences Simply Wall St Growth Rating: ★★★★★☆ Overview: Shanghai OPM Biosciences Co., Ltd. operates by offering cell culture media and CDMO services both in China and internationally, with a market capitalization of CN¥6.39 billion. Operations: The company generates revenue through the provision of cell culture media and CDMO services across domestic and international markets. It holds a market capitalization of approximately CN¥6.39 billion. Shanghai OPM Biosciences, amidst a challenging year with earnings contraction by 67.3%, still projects robust future growth, with anticipated revenue and earnings increases of 23.8% and 53.6% annually, outpacing the Chinese market norms of 12.9% and 23.9%, respectively. Despite a significant drop in profit margins from 19.4% to 5.4%, the firm maintains positive free cash flow and is set for a pivotal shareholders meeting that could steer its strategic direction amidst these volatile conditions. This biotech entity's commitment to innovation is evident from its R&D focus, although specific financials on this expenditure aren't disclosed here; such investment is critical in sustaining long-term competitiveness in the fast-evolving sector where technological advancements rapidly redefine market dynamics. Click to explore a detailed breakdown of our findings in Shanghai OPM Biosciences' health report. Review our historical performance report to gain insights into Shanghai OPM Biosciences''s past performance. Taiwan Union Technology Simply Wall St Growth Rating: ★★★★★☆ Overview: Taiwan Union Technology Corporation manufactures and sells copper foil substrates, adhesive sheets, and multi-layer laminated boards both in Taiwan and internationally, with a market capitalization of NT$87.56 billion. Operations: The company focuses on producing copper foil substrates, adhesive sheets, and multi-layer laminated boards for both domestic and international markets. Its revenue model is centered around these core products, contributing significantly to its financial performance. Taiwan Union Technology has demonstrated robust financial performance, with a significant 19.2% annual revenue growth and an impressive 31.8% increase in earnings per year, outstripping the Taiwanese market norms of 10.1% and 15.3%, respectively. The company's commitment to innovation is underscored by its R&D investments, crucial for maintaining competitiveness in the rapidly evolving tech landscape. Recent dividends and amendments to company bylaws reflect proactive governance, aligning with strategic goals that could shape its trajectory in Asia's high-tech sector. Take a closer look at Taiwan Union Technology's potential here in our health report. Gain insights into Taiwan Union Technology's past trends and performance with our Past report. CELSYS Simply Wall St Growth Rating: ★★★★☆☆ Overview: CELSYS, Inc. operates in the content creation solutions sector in Japan and has a market capitalization of ¥53.32 billion. Operations: The company focuses on providing content creation solutions in Japan. It operates through various revenue streams, primarily driven by software sales and related services. CELYS is actively enhancing its financial agility and market presence, as evidenced by its recent share repurchase program aimed at improving capital efficiency. The initiative to buy back 500,000 shares for ¥500 million underscores a strategic approach to capital management amidst evolving business conditions. Additionally, the establishment of CELSYS UK Ltd. marks a significant step in expanding global payment solutions, aligning with the company's growth trajectory in software offerings like CLIP STUDIO PAINT. This expansion not only diversifies their service platform but also promises to bolster corporate value over time. With an impressive forecast of 24.2% annual earnings growth and a revenue increase expectation of 10.3% per year outpacing Japan's market average, CELSYS is poised to strengthen its position in the competitive tech landscape through these calculated operational enhancements and financial strategies. Dive into the specifics of CELSYS here with our thorough health report. Understand CELSYS' track record by examining our Past report. Turning Ideas Into Actions Click this link to deep-dive into the 180 companies within our Asian High Growth Tech and AI Stocks screener. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688293 TPEX:6274 and TSE:3663. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
